Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of “Moderate Buy” by Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $10.80.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th.

Insiders Place Their Bets

In other news, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the sale, the vice president now owns 54,634 shares in the company, valued at approximately $68,838.84. This represents a 41.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joseph P. Hagan acquired 50,000 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were acquired at an average price of $1.09 per share, with a total value of $54,500.00. Following the acquisition, the chief executive officer now owns 260,808 shares in the company, valued at approximately $284,280.72. The trade was a 23.72 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 over the last 90 days. Company insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Regulus Therapeutics

Hedge funds have recently made changes to their positions in the company. Creative Planning acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $26,000. SG Americas Securities LLC acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $33,000. Jane Street Group LLC acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $46,000. JPMorgan Chase & Co. increased its position in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the period. Finally, Barclays PLC increased its position in shares of Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Stock Performance

Shares of NASDAQ RGLS opened at $1.32 on Thursday. The firm has a market capitalization of $86.46 million, a price-to-earnings ratio of -1.23 and a beta of 1.58. The stock has a 50 day moving average price of $1.44 and a 200 day moving average price of $1.53. Regulus Therapeutics has a 52-week low of $0.83 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.